Similar articles

• Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.

  Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, Deshmukh M, Rice A, Popat S. Nicholson AG, et al. J Thorac Oncol. 2010 Apr;5(4):436-41. doi: 10.1097/JTO.0b013e3181c6ed9b. J Thorac Oncol. 2010. PMID: 20068475
• Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

  Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M. Schneider CP, et al. J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa. J Thorac Oncol. 2008. PMID: 19057271 Clinical Trial.
• Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers.

  Chang YL, Wu CT, Shih JY, Lee YC. Chang YL, et al. Ann Surg Oncol. 2011 Feb;18(2):543-50. doi: 10.1245/s10434-010-1295-6. Epub 2010 Sep 2. Ann Surg Oncol. 2011. PMID: 20811949
• [Experience on epidermal growth factor receptor gene mutation analysis in non-small cell lung cancer].

  Zhang J, Gao J, Liang ZY, Liu TH. Zhang J, et al. Zhonghua Bing Li Xue Za Zhi. 2011 Oct;40(10):712-4. Zhonghua Bing Li Xue Za Zhi. 2011. PMID: 22321558 Review. Chinese. No abstract available.
• Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.

  Sacher AG, Gandhi L. Sacher AG, et al. JAMA Oncol. 2016 Sep 1;2(9):1217-22. doi: 10.1001/jamaoncol.2016.0639. JAMA Oncol. 2016. PMID: 27310809 Review.